Previous 10 | Next 10 |
home / stock / gild / gild articles
Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is a mo...
U.S. National Institutes of Health has launched two clinical trials to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in c...
On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results fro...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return...
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim re...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.84% on an annualized basis producing an average annual return...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...